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pro-inflammatory pathways associated with
MyD88 and TRIF
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b-Defensins are cationic host defense peptides that form an amphipathic structure
stabilized by three intramolecular disulfide bonds. They are key players in innate and
adaptive immunity and have recently been shown to limit the production of pro-
inflammatory cytokines in TLR4-stimulated macrophages. In the present study, we
investigate the mechanism underlying the anti-inflammatory effect of human b-defensin 3
(hBD3). We show that the canonical structure of hBD3 is required for this immunosup-
pressive effect and that hBD3 rapidly associates with and enters macrophages. Exam-
ination of the global effect of hBD3 on transcription in TLR4-stimulated macrophages
shows that hBD3 inhibits the transcription of pro-inflammatory genes. Among the altered
genes there is significant enrichment of groups involved in the positive regulation of NF-jB
including components of Toll-like receptor signaling pathways. We confirm these obser-
vations by showing corresponding decreases in protein levels of pro-inflammatory cyto-
kines and cell surface molecules. In addition, we show that hBD3 reduces NF-jB signaling
in cells transfected with MyD88 or TRIF and that hBD3 inhibits the TLR4 response in both
MyD88- and TRIF-deficient macrophages. Taken together these findings suggest that the
mechanism of hBD3 anti-inflammatory activity involves specific targeting of TLR signaling
pathways resulting in transcriptional repression of pro-inflammatory genes.
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Introduction
The mammalian immune system has developed a multitude of
mechanisms to deal with invading micro-organisms. b-Defensins
are cationic, antimicrobial peptides believed to defend the host
against invading microbes by inhibiting bacterial cell wall
biosynthesis [1]. In addition, b-defensins have immunomodula-
tory properties and chemoattract monocytes, lymphocytes and
DCs [2], suggesting that these antimicrobial peptides play a role
in the link between innate and adaptive immunity. Human
b-defensins chemoattract immune cells and hBD3 in particular
has been shown to bind a variety of receptors including CCR6,
CCR2 [3, 4] melanocortin receptors [5] and the chemokine
receptor CXCR4 [6].
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b-Defensins have been shown to increase expression of pro-
inflammatory mediators in keratinocytes [7] and immune cells.
In immature DCs, murine DEFB2 has been described as a ligand
for Toll-like receptor 4 (TLR4) and induces maturation and co-
stimulatory molecules [8]. In addition, hBD3 has been shown to
induce expression of co-stimulatory molecules CD80, CD86 and
CD40, on human monocytes and myeloid DCs in a TLR1/2-
dependent manner [9]. Conversely, some studies have described
an inhibitory effect of defensins. DEFB123 prevents LPS-mediated
effects in vitro and in vivo [10], and a range of a- and b-defensins
have significantly inhibited the expression of LPS-induced pro-
inflammatory cytokines [11, 12]. In some cases the researchers
attribute the suppressive effects of defensins on the immune
response to defensin-LPS binding [10, 12] as has previously been
described for the bactericidal/permeability increasing protein
from granulocytes [13] and the cathelicidin LL-37 [14].
We previously described an anti-inflammatory role of hBD3 by
demonstrating that hBD3 inhibits the accumulation of TNF-a and
IL-6 proteins in LPS-stimulated BM-derived macrophages both in
vitro and in vivo [15]. The mechanism of this activity is unknown
and it may be that, like other defensins [8, 10], hBD3 is binding
LPS in the extracellular space. hBD3 may also bind to TLR4
thereby preventing the TLR4-LPS interaction. However, we have
previously shown that hBD3 does not bind LPS in the limulus
amebocyte assay and that hBD3 also inhibits a non-TLR ligand,
CD40L [15]. In the present study, we further clarify the
mechanism of hBD3 anti-inflammatory action by examining the
requirement for structural integrity; the uptake of hBD3 by
macrophages; the transcriptional response of macrophages and
the intracellular signaling pathways suppressed by hBD3.
Results
The importance of the structural integrity of hBD3
We have previously shown that hBD3 does not induce a pro-
inflammatory response, but suppresses the cytokine response of
macrophages to LPS. Other researchers however, have found
hBD3 to have pro-inflammatory effects in immune cells [9]. We
investigated whether the structural integrity of hBD3 plays an
important part in the immune-modulating effect of this peptide.
Structure has previously been shown to affect hBD3–receptor
interactions and chemotactic activity [16]. hBD3 has an
N-terminal a-helix followed by three antiparallel b sheets, which
is stabilized by six canonical cysteines and three disulfide bonds
[17]. To determine whether the disulfide bond stabilization of
hBD3 is important for the anti-inflammatory effect, we validated
the oxidation of our hBD3 preparation and also synthesized a
form of hBD3 where the six cysteine residues were replaced by
serines (hBD3cys-ser). This peptide has the same net charge and
hydrophobicity as the parent peptide. hBD3cys-ser did not inhibit
LPS-induced TNF-a and in fact significantly enhanced the pro-
inflammatory effects of LPS, in contrast to the anti-inflammatory
effects observed with folded hBD3 (Fig. 1A). In the absence of
LPS, hBD3cys-ser had no effect on TNF-a levels. None of the
above treatments affected cell viability as MTT assay measure-
ments were comparable between treated cells and untreated
controls. These data suggest that hBD3, in both structural forms,
does not induce a pro-inflammatory response, but in the presence
of LPS, hBD3 that is not canonically folded enhances the pro-
inflammatory effects of LPS in macrophages.
hBD3 rapidly enters macrophages
To investigate whether hBD3 remains at the cell surface or enters
the cell, we treated RAW264.7 macrophage cells with TAMRA-
labeled hBD3 (hBD3TAMRA) and used live cell imaging to track
uptake of the labeled peptide. Immediately after addition,
hBD3TAMRA was evident on the surface of the cell membrane
(Fig. 1B, panel b). After 10mins labeled hBD3 was visualized in
the cell cytoplasm, and did not appear to enter the nucleus
(Fig. 1B, panel d). hBD3TAMRA continued to accumulate both
inside the cell and on the cell surface over 2 h (Supporting
Information Movie) whereas TAMRA label alone did not enter
cells over a period of 24 h (Supporting Information Fig. 1). The
presence of the TAMRA label did not affect the anti-inflammatory
properties of hBD3 (Fig. 1C).
To demonstrate that the anti-inflammatory effect of hBD3 was
not simply due to hBD3-LPS binding, we treated RAW264.7 cells
with hBD3 for 1 h and washed the cells thoroughly before
stimulating with LPS. Removal of hBD3 from the extracellular
environment did not alter the ability of hBD3 to inhibit the pro-
inflammatory effects of LPS (Fig. 1D). In comparison, the anti-
inflammatory effect of polymyxin B, a cyclic hydrophobic peptide
known to bind LPS, was significantly affected by washing. These
results in combination with our previous finding that hBD3
significantly inhibits the effects of LPS, even when cells are
treated with LPS for 1 h before the addition of hBD3, strongly
suggests that most of the hBD3 inhibitory effect is occurring
downstream of TLR4 activation by LPS.
hBD3 represses TLR4-mediated transcription
To further investigate the molecular mechanisms underlying the
hBD3 effect, we profiled global gene expression changes in
macrophages. A chemically defined LPS molecule, which consists
of lipid A with an attached 3-deoxy-D-manno-octulosonic acid,
termed KDO2-Lipid A (KLA) has been shown to induce compar-
able bioactivity and displays a similar gene expression profile to
wildtype LPS from Gram-negative bacteria [18]. We compared
the effects of hBD3 on LPS- and KLA-stimulated BMDM and
found that hBD3 significantly inhibited TNF-a induced by both
LPS and KLA (Fig. 2A). To examine the effects of hBD3 on gene
expression, BMDM from Balb/c mice were treated with KLA in
the presence and absence of hBD3, hBD3 alone or left untreated.
Previous studies have shown a marked increase in the transcrip-
tion of pro-inflammatory cytokines at 6 h [19], we therefore
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examined patterns of expression associated with hBD3 and/or
KLA treatment at 6 h.
As expected the analysis of the microarray data revealed
evidence of significant expression changes in response to KLA.
Compared with unstimulated macrophages, 6 h KLA treatment
resulted in 5494 differentially expressed genes (multiple testing
adjusted p-value of o0.05). This list of genes (Supporting
Information Fig. 2, list 1) contained many genes reported
to be altered in LPS-stimulated macrophages [20] and we
observed a significant positive correlation (Pearson’s r50.585,
po0.01) with the LPS gene expression profile presented by Amit
et al. [21].
Exposing macrophages to a combination of KLA and hBD3
dramatically reduced the number of genes significantly differen-
tially expressed, from 5494 to 1779 (Supporting Information
Fig. 2, list 2). We examined the distributions of expression
changes, as log fold change (log FC) values, for all genes on the
array between untreated cells and two treatments: KLA and KLA
plus hBD3. The changes in distributions revealed a dramatic
reduction in the spread of log FC values in the presence of hBD3,
consistent with hBD3 globally attenuating the transcriptional
response to KLA (Fig. 2B). We used the bioinformatics tool
DAVID [22, 23] and identified significant KEGG (Kyoto Ency-
clopedia of Genes and Genomes) pathway enrichment among the
genes differentially expressed between KLA treatment and KLA
treatment in the presence of hBD3. Many of the genes suppressed
by hBD3 are involved in both the TLR signaling and NOD-like
receptor signaling pathways (Supporting Information Table 1).
The genes demonstrating the highest log FC values after KLA
treatment alongside the corresponding decreases in expression
with treatment in the presence of hBD3 are shown in Fig. 2C. The
expression values for KLA treatment are significantly different
from log FC values for combined KLA and hBD3 treatment
(po0.001, Mann-Whitney test). These data suggest that hBD3
limits the effects of TLR4 stimulation by KLA by inhibiting gene
transcription and/or events leading to gene transcription.
Figure 1. hBD3 anti-inflammatory effect is dependent on structure and cellular uptake. (A) RAW264.7 cells were treated with 50 ng/mL LPS with
and without either canonically folded hBD3 (hBD3-F) or linearised hBD3 (hBD3-L) each at 5 mg/mL for 4 h. TNF-a in tissue culture supernatant was
measured by ELISA, n5 3. Data are presented as means7SEM, significance assessed by unpaired t-test, po0.001, po0.05 was calculated by
comparing LPS plus hBD3 with LPS alone. (B) RAW 264.7 cells cultured on glass overnight were exposed to 5 mg/mL hBD3TAMRA. A z-series was
collected for each treatment with an interplane distance of 0.2mM. The optimal z-plane from each stack is shown. The fluorescent images show
the cells immediately (b) and 10 mins (d) after exposure to the peptide, with the corresponding brightfield images shown in (a) and (c). Scale bar
10 mM. (C) TNF-a in tissue culture supernatant from RAW264.7 treated as above, was measured by ELISA, n5 3. Data are presented as means7SEM,
significance assessed by unpaired t-test, po0.001, was calculated by comparing LPS plus hBD3 or hBD3TAMRA, with LPS alone. (D) RAW264.7 cells
were pre-treated in serum-free media with 5 mg/mL hBD3 or 10mg/mL polymyxin B for the indicated times, washed twice with PBS, then returned
to conditioned serum-free media before incubation with 50 ng/mL LPS for 4 h. TNF-a in tissue culture supernatant from was measured by ELISA,
n5 3. Data are presented as means7SEM, significance assessed by unpaired t-test, po0.001, was calculated by comparing LPS plus hBD3 with
LPS alone.
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hBD3 repression of transcription is reflected by a
reduction in protein levels
We confirmed that the repressive effects of hBD3 on gene
transcription were reflected by inhibitory effects on the resulting
gene products. Measurement of IL-6, IL-12p40 and RANTES
proteins (the gene products of Il6, Il12a and Ccl5, respectively)
after 18 h treatment with KLA or LPS without or with hBD3
reflected the gene expression results. These protein measure-
ments were carried out in both BMDMs (induced from BM by
CSF-1) and conventional myeloid dendritic cells (cDC) (induced
from BM by GM-CSF) to examine potential differences
in hBD3 effect between cells with different backgrounds
of cytokine/chemokine environment. Exposure of BMDM to
50ng/mL of the TLR4 ligands, resulted in a significant increase
in IL-6, IL-12p40 and RANTES (Fig. 3A). The presence of 5mg/mL
of hBD3 significantly reduced the induction of these cytokines
(Fig. 3A) and IFN-b (Supporting Information Fig. 3). The same
inhibitory effects were observed in cDCs (Fig. 3B), despite
different basal levels of cytokine (particularly IL-12p40) in the
untreated cells.
In addition, the suppression of co-stimulatory molecule gene
expression by hBD3 was confirmed using flow cytometric analy-
sis. Co-stimulatory molecules, CD40 and CD86, are often used as
a measure of macrophage activation. In agreement with the gene
expression data, LPS treatment resulted in the expression of
CD40 and CD86 proteins on the cell surface. This co-stimulatory
molecule expression was significantly suppressed in the presence
of hBD3 (Fig. 3C and D and Supporting Information Fig. 4).
These data demonstrate that the repression of Il6, Il12a, Ccl5,
CD40 and CD86 transcripts by hBD3 is consistent with a reduc-
tion in the protein levels as measured by ELISA or flow cytometry.
hBD3 is associated with a global attenuation of early
LPS effects
TLR4 stimulation of BM-derived immune cells results in
significant transcriptional changes within 1 h [24, 25]. As we
have shown that hBD3 is in the cell cytoplasm at this time we
sought to determine whether these early transcriptional events
are suppressed by hBD3. We have shown that hBD3 inhibition of
Figure 2. hBD3 inhibits LPS/KLA induced transcription. (A) BMDMs were treated with 50 ng/mL LPS or KLA in the presence and absence of 5 mg/mL
hBD3 for 18 h. TNF-a in the supernatant was measured by ELISA, n5 3 (BMDMs from three separate mice). Data are presented as means7SEM,
significance assessed by unpaired t-test, po0.001 was calculated by comparing LPS or KLA plus hBD3 with LPS or KLA alone. (B) Global gene
expression changes in BMDMs treated for 6 h with 50 ng/mL KLA in the presence and absence of 5 mg/mL hBD3. Each box represents the
interquartile range centered upon the median (and containing 50% of the values), the whiskers denote 1.5 times the interquartile range, and the
circles represent outlier values beyond the whiskers. For each treatment (x-axis) the distribution of log FC values (y-axis) for all genes on the array
are shown relative to untreated cells. Each circle on the graph represents a gene on the array. (C) Examples of genes suppressed by hBD3. The genes
differentially expressed after BMDM stimulation with KLA (striped bars) were compared to the genes differentially expressed after BMDM
stimulation in the presence of hBD3 (black bars). Each bar represents the average log fold change value compared to untreated BMDMs. Each
treatment has been carried out in triplicate on three separate mice. po0.001 Mann–Whitney test.
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LPS-induced TNF-a is more complete than hBD3 inhibition of
KLA-induced TNF-a (see Fig. 2A), we therefore treated macro-
phages for 1 h with LPS in an effort to optimize the experiment at
this early time point. This also replicates the TLR4 stimulation
demonstrated in previous studies [21, 24] which used LPS from
Escherichia coli serotype 055:B5. The list of genes increased by
LPS at 1 h (Supporting Information Fig. 2, list 4) demonstrated a
significant positive correlation (Pearson’s r50.579, po0.01) with
a comparable data set: the 1 h LPS gene expression profile
presented by Amit et al. [21]. Treatment with LPS in the presence
of hBD3 at 1 h again displayed patterns consistent with hBD3
globally attenuating the response to LPS (Supporting Information
Fig. 5).
At the 1 h time point only 21 genes were found to be signifi-
cantly differentially expressed, which is insufficient to generate
significant enrichment results using traditional, hard threshold-
based methods such as DAVID. However, we were able to seek
broader trends in these data using GOrilla [26], a more sensitive
approach to GO enrichment analysis that is not dependent on
arbitrary thresholds of significance. Using this approach it was
found that the enrichment of GO terms in the most altered genes
from the 1 h LPS data set reflected the known effects of LPS on
macrophage functions. Annotation terms related to the immune
response, inflammation and apoptosis were strongly and signifi-
cantly enriched within the LPS-induced up-regulated genes.
Comparison with the data set generated by LPS treatment in the
presence of hBD3 (Supporting Information Fig. 2, list 5) revealed
that many of the same terms were significantly enriched but
fewer genes were involved (Supporting Information Table 2)
with some of these being actively repressed. This actively
repressed group was evident as 8401 genes, all of which were up-
regulated by LPS (positive log FC) but down-regulated by LPS in
the presence of hBD3 (negative log FC). We sought to identify
significant enrichment of particular pathways among the genes
showing the strongest levels of repression using GOrilla. Analysis
of GO term enrichment within this sorted list revealed significant
terms relating to apoptosis (GO:0006915), immune system
process (GO:0002376) and positive regulation of NF-kB tran-
scription factor activity (GO:0051092) (Supporting Information
Table 3). The latter group included genes from TLR signaling
pathways, such as Tlr2, MyD88 and IRAK2, suggesting that hBD3
suppresses TLR signaling components as early as 1 h post-treat-
ment. Findings relating to apoptosis are potentially of interest as
hBD3 has been shown to inhibit apoptosis of neutrophils [27].
hBD3 has no major effects in the absence of LPS
The overall distributions of log FC (Fig. 2B and Supporting
Information Fig. 3) for hBD3, LPS and combined hBD3 and
LPS treatments show that hBD3 had minimal effects on expression,
as hBD3 logFC values more closely approximate zero than the
other treatment data sets. No genes were found to be significantly
differentially expressed after treatment of BMDM with hBD3 and
analysis using the GOrilla method failed to identify any broader
enrichment trends among the most altered genes, demonstrating
that hBD3 has little measurable effect on gene expression in the
absence of LPS. This finding was reflected in the lack of cytokine
response in macrophages exposed to hBD3 (Fig. 3A).
hBD3 inhibits both MyD88 and TRIF signaling
The gene expression profiles of TLR4-activated macrophages in
the presence and absence of hBD3, indicated that hBD3 resulted
in down-regulation of genes involved in TLR signaling pathways.
Figure 3. hBD3 inhibits production of TLR4-induced IL-6, IL-12p40,
RANTES and co-stimulatory molecules. (A) BMDMs and (B) cDCs were
treated with 50 ng/mL LPS or KLA in the presence or absence of 5 mg/mL
hBD3 for 18 h. Cytokine levels in the cell culture supernatants were
measured by ELISA, n5 3 (BMDMs from three separate mice and cDCs
from three further separate mice). Data are presented as means7SEM,
significance assessed by unpaired t-test, po0.001, po0.01, po0.05
was calculated by comparing LPS or KLA plus hBD3 with LPS or KLA
alone. (C, D) BMDM were treated with 50 ng/mL LPS in the presence and
absence of 5 mg/mL hBD3. Cell surface expression of (C) CD40 and (D)
CD86 was assessed by flow cytometry. Data are presented as mean
fluorescence intensity (MFI) demonstrating a significant increase in
CD40 (po0.01) and CD86 (po0.05) after treatment with LPS. This
increase was not observed after treatment with LPS in the presence of
hBD3 or hBD3 alone, n5 3 (BMDMs from three separate mice,
significance assessed by one-way ANOVA with Tukey post test).
Eur. J. Immunol. 2011. 41: 3291–3300 Immunomodulation 3295
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This suppression is likely to be the cause of the observed down-
regulation of NF-kB and inflammatory gene transcription.
Downstream of TLR4, LPS activates both MyD88-dependent
and independent (TRIF dependent) pathways [28]. To further
investigate the effects of hBD3 on these pathways, we transiently
expressed MyD88 and TRIF in HEK 293 cells with an NF-kB-
luciferase reporter plasmid (NF-kB-luc). Transfecting with either
MyD88 or TRIF plasmid resulted in expression of MyD88 or TRIF
protein and subsequent induction of Nf-kB-luc activity (Fig. 4A
and B). Both MyD88- and TRIF-induced NF-kB-luc activity was
inhibited in a dose-dependent manner when hBD3 was
co-transfected at increasing concentrations (50, 100 and
200ng) (Fig. 4A and B). The concentration of total transfected
plasmid was kept constant by using increasing amounts of empty
vector as the amount of hBD3 plasmid decreased. Empty vector
had no effect on NF-kB-luc signal (Fig. 4A). This demonstrates
that hBD3 targets the Myd88 and TRIF pathways downstream of
both the ligand (LPS) and the receptor (TLR4).
We further validated this result by examining the ability of hBD3
to suppress an inflammatory response in the absence of MyD88 or
TRIF using MyD88/ and TRIF/ mutant mice. BMDM from
wildtype (w/t) C57BL/6 mice were stimulated with 50ng/mL LPS
to induce TNF-a and RANTES. This induction was significantly
suppressed in the presence of hBD3 (Fig. 4C and D). BMDM from
MyD88/ mice did not induce TNF-a in response to LPS, indicating
that TNF-a production by LPS is MyD88 dependent, whereas
RANTES production is not reduced in the absence of MyD88. In the
presence of hBD3, RANTES was inhibited to a similar extent to the
inhibition afforded by the endosomal inhibitor chloroquine (CQ)
(Fig. 4D). Treatment of TRIF/ BMDM with LPS resulted in an
increase in TNF-a (through the MyD88 pathway) which was inhib-
ited in the presence of hBD3. The response to pI:C in these TRIF null
macrophages was abrogated, verifying the inability of these cells to
signal through the TRIF pathway. RANTES was only minimally
increased by LPS in TRIF/ BMDM, however this increase was also
suppressed in the presence of hBD3 (Fig. 4D). These data show that
hBD3 prevents both MyD88 and TRIF signaling.
Discussion
The current literature on the immunomodulatory activity of
defensins and indeed other antimicrobial, cationic amphipathic
peptides, such as LL-37, indicates that the function of anti-
microbial peptides in immunity is complex and unresolved [9, 14,
15, 29, 30]. There is incomplete evidence to suggest either a pro-
inflammatory or anti-inflammatory role, and it may be that like
LL-37, b-defensins are multifunctional modulators of the immune
response, demonstrating pro-inflammatory effects at high
concentrations but anti-inflammatory effects at lower concentra-
tions [31]. It is possible that hBD3 is induced at high levels at the
site of pathogen entry, causing a pro-inflammatory response
involving chemoattraction of macrophages and other immune
cells. As the danger is neutralized and levels of hBD3 and other
pro-inflammatory molecules decrease, hBD3 may then have a
role in resolving inflammation.
In previous work, we focused on the effects of hBD3 on
protein levels of TNF-a and IL-6 and showed no measurable
increase in these cytokines in hBD3-treated macrophages [15].
The gene expression analyses carried out in the present study
allowed a more comprehensive investigation of the effects of
hBD3 at the transcription level. Enrichment analysis of all
differentially expressed genes, failed to identify any pro-inflam-
matory markers after hBD3 treatment. In contrast, hBD3 has
been shown to induce cell surface co-stimulatory molecule
Figure 4. hBD3 inhibits intracellular signaling via both the MyD88 and
TRIF pathways. (A, B) HEK 293 cells were transfected with an NF-kB-
luciferase reporter construct in combination with expression for either,
(A) MyD88 or (B) TRIF and 50–200 ng of hBD3 cDNA expression construct.
NF-kB luciferase activity was measured after 18 h. Data were normal-
ized against tk-renilla luciferase and expressed as arbitrary units. Data
are presented as mean7SEM, significance assessed by unpaired t-test,
po0.01 was calculated by comparing MyD88 (or TRIF) co-transfected
with 200 ng empty vector (gray bar) to MyD88 (or TRIF) co-transfected
with increasing amounts of hBD3 plasmid (solid bars). n5 3
(e.v.5 empty vector alone). (C, D) BMDMs from w/t C57BL/6, MyD88/
and TRIF/ mice were stimulated with 50 ng/mL LPS in the presence
and absence of 5 mg/mL hBD3 or CQ. Levels of (C) TNF-a and (D) RANTES
in tissue culture supernatants were measured by ELISA. Data are
presented as means7SEM, significance assessed by unpaired t-test,
po0.001, po0.05 was calculated by comparing LPS plus hBD3 with
LPS alone. n5 4 (BMDM from four separate mice).
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expression in human monocytes and myeloid DCs [9]. We
observed no increase in co-stimulatory molecules after hBD3
treatment and in fact observed a reduction in LPS-induced CD40
and CD86 at both the gene transcript and protein level (Figs. 2C,
3C and D). We wondered whether the contrasting results may be
explained by structural integrity of the hBD3 molecule. We show
that in the absence of LPS neither canonically folded hBD3 nor
hBD3 without disulfide bonds induce a pro-inflammatory cyto-
kine response. However, when testing the ability of hBD3cys-ser
to inhibit the effects of LPS we discovered that hBD3cys-ser in the
presence of LPS induced a pro-inflammatory response signifi-
cantly higher than that of LPS alone.
It is possible that the work in vitro by others reflects the use of
an LPS-contaminated or non-canonically folded form of the
peptide. In vivo defensin molecules may be destabilized by
reduction in the disulfide bonds and recently it was shown that
reduced hBD1 demonstrated enhanced antimicrobial activity
[32]. We have previously demonstrated the ability of hBD3 to
limit the pro-inflammatory effect of LPS in mice, indicating that
disulfide bond reduction is unlikely to occur in vivo [15].
Gene expression analysis indicated that inhibition by hBD3
affected gene transcription, therefore hBD3 does not act on the
available TNF-a/IL-6 reservoir of protein already present in the
cell. This provides evidence that hBD3 interferes with LPS
signaling at some point between LPS-TLR4 receptor binding and
transcription factor activation. GO term enrichment analysis of
transcripts at 1 h shows that hBD3 down-regulates components of
TLR signaling pathways. This in turn leads to the observed
suppression of chemokine and cytokine transcripts at 6 h, and
also at this time many components of TLR signaling remain
down-regulated (Fig. 2C).
Downstream of TLR4, LPS utilizes both MyD88-dependent
and TRIF-dependent signaling pathways. In macrophages,
MyD88 is recruited to activate TLR4 by MAL and results in early
NF-kB and AP-1-mediated induction of pro-inflammatory cyto-
kines [33]. Activation of TLR4 also promotes receptor endocy-
tosis with Rab11a, which causes a release of TLR4 for subsequent
interaction with TRAM and TRIF [34]. There is then a later wave
of NF-kB, AP-1 and IRF3 activation and subsequent induction of
IFN-regulated genes [35]. At 1 h after LPS treatment, hBD3 is
very effective at inhibiting the effect of LPS where activation is
assumed to be via the early MyD88-dependent pathway, implying
that hBD3 targets MyD88 signaling. This result is supported by
the fact that the hBD3 inhibitory effect is evident in cells trans-
fected with MyD88-expression construct and also in LPS-stimu-
lated macrophages lacking TRIF (therefore only signaling via
MyD88). However, hBD3 also suppresses TRIF signaling in both
HEK 293 cells expressing TRIF and in LPS-stimulated MyD88-
deficient macrophages. hBD3 must therefore target a signaling
component shared by both the MyD88 and TRIF pathways or
target components in both pathways. The downstream compo-
nents of both the MyD88 and TRIF pathways are currently being
investigated as potential targets of hBD3 action.
We propose that hBD3 enters immune cells and prevents
activation of a pro-inflammatory response by specifically binding
to component(s) of TLR signaling pathways. A similar mechanism
has recently been described as an immune evading mechanism
for Vaccinia virus which encodes a protein which prevents TLR
signaling by binding the multiple cytoplasmic Toll/IL-1R (TIR)
domain-containing adaptor proteins, MAL and TRAM [36]. These
researchers found that the inhibitory effects were specific to
TLR4. A comparison of hBD3 and the active component of the
Vaccinia virus protein (VIPER) revealed no sequence similarities
between the two peptides. We are currently continuing to
investigate the protein targets of hBD3 to determine the point at
which hBD3 prevents TLR signaling.
Components of TLR pathways are potential therapeutic
targets in inflammatory and autoimmune disease [37]. Over
activation of TLR4 can give rise to endotoxic shock often resulting
in sepsis and death. In addition, TLR4 can respond to endogenous
damage-associated signals and give rise to sterile inflammation, a
mechanism recently suggested for atherosclerosis and Alzhei-
mer’s disease [38]. Among the population the variability in
b-defensins copy number, specifically hBD3, may result in
differing susceptibility of some individuals to disease-induced
inflammation [39, 40]. Clarification of the molecular basis of the
interaction of hBD3 with TLR inflammatory pathway may be of
direct clinical relevance, and in addition shed light on the role of
hBD3 in inflammatory disease.
Materials and methods
Reagents
Ultra-pure lipopolysaccharide (LPS) from E. coli 0111:B4,
lipoteichoic acid (LTA), Pam3CSK4, polyI:C, R848 and IFN-g
were purchased from InvivoGen (San Diego, USA), di[3-deoxy-
D-manno-octulosonyl]-lipid A (KDO2-Lipid A) from Avanti Polar
Lipids (Netherlands). CQ was purchased from Autogen Bioclear
UK (Wiltshire, UK). M-CSF and GM-CSF and ELISA DuoSets were
obtained from R&D Systems (Abington, UK). hBD3 (GIINTLQKY-
YCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK) was purchased
from Peptides International or synthesised by solid-phase peptide
synthesis as described.
Solid-phase peptide synthesis and oxidative folding
All peptides were produced on an Applied Biosystems 433A
peptide synthesizer by standard Fmoc (fluorenylmethyloxy-
carbonyl chloride) chemistry (full details are in Supporting
Information).
Cell-lines and primary cell preparation
RAW264.7 cells were maintained in DMEM (GIBCO) containing
10% fetal bovine serum (FBS), essential amino acids and
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antibiotics. Balb/c and C57 Black/6 mice were obtained from
Charles River (UK) and MyD88/ and TRIF/ were a kind
gift from David Gray (University of Edinburgh). Primary cells
were generated from femur BM and grown for 7–10 in DMEM
containing 10% fetal bovine serum and either 20 ng/mL M-CSF to
generate macrophages or 20 ng/mL GM-CSF to generate cDCs.
Cells were seeded at 2105 into 48-well plates and grown
without growth factor for 24 h prior to treatment. Replicate
experiments were performed with separate primary cell prepara-
tions from at least three mice for each experiment.
Cell culture for live cell image analysis
RAW264.7 cells were cultured overnight in 24-well glass-
bottomed plates coated with poly-ethylene imine (Sterilin,
London, UK) in DMEM (supplemented as above). hBD3 labeled
with the TAMRA fluorochrome (HBD3TAMRA) was added to the
media at 5 mg/mL just prior to image analysis.
Image analysis
Live cell image analysis was carried out using a Zeiss Axiovert 200
fluorescence microscope (full details are in Supporting Informa-
tion). Z-stacks were captured over a distance of 30 mM at 0.2 mM
per slice. An image was selected from the center of the stack to
show the distribution of HBD3TAMRA within the cell. Images have
been processed with a g adjustment of 0.4 to enhance the
midrange values.
Microarray protocol and analysis
RNA was extracted, with RNA bee (AMS Biotechnology,
Abingdon, UK) using standard methods, from BMDM (three
biological replicates per treatment) treated with hBD3 (5 mg/mL),
LPS or KLA (50 ng/mL), a combination of hBD3 and LPS or KLA
or untreated. Amplified, biotinylated cRNA was synthesized using
Illuminas TotalPrep Amplification Kit (Ambion, Austin, Texas)
and microarray experiments were performed using 2 Illumina
MouseWG-6 v2.0 BeadChips for 6 h treatments, and Illumina
MouseRef-8 v2.0, for 1 h treatments. The data sets are available
from Gene Expression Omnibus (GEO) accession numbers
GSE25870 and GSE25871. Briefly, the analysis consisted of
standard normalization procedures, followed by a widely used
linear model approach to the detection of differential expression,
coupled with a multiple testing correction. Full details of the
microarray analysis are in Supporting Information.
Cell treatment and ELISA
Cells were treated with LPS (50 ng/mL) or KLA (50 ng/mL), in
the presence or absence of hBD3 (5 mg/mL) in serum-free media
then incubated at 371C, 5% CO2 for 18 h. Cell viability was
measured using TACSTM MTT assay (R&D Systems). Where
appropriate, cells were pre-incubated with hBD3 for the required
time, followed by two washes with PBS before treating with LPS
in conditioned media. Supernatants were collected and centri-
fuged then levels of TNF-a, IL-6, IL-12p40 and RANTES were
measured using DuoSet ELISA (R&D Systems) according to
manufacturer’s instructions. Where appropriate, statistical signif-
icance was determined by an unpaired t-test using the GraphPad
software. For all statistical analyses, po0.05 was considered
significant. Values are expressed as mean7SEM.
Cell transfection and luciferase detection
Full-length hBD3 cDNA was amplified with restriction fragment
linkers (NotI and XhoI) and cloned into expression vector
pcDNA3.1 (Invitrogen, UK). HEK293 cells were co-transfected
with NF-kB luciferase plasmid and MyD88 (EBG6P-MyD88; a
kind gift from Prof. Cohen) or TRIF (pflag-CMV2 TRIF; a kind gift
from Prof. Bowie) expression plasmids in combination with
increasing amounts of hBD3 expression plasmid. Total trans-
fected DNA was kept constant with pcDNA 3.1 empty vector.
Dual-luciferase kits (Promega) were used for subsequent analysis.
NF-kB Firefly luciferase activity was normalized for cell transfec-
tion with tk-renilla luciferase co-transfection.
Co-stimulatory molecule detection
Expression of CD40 and CD86 on the surface of BMDM following
treatment with LPS and/or hBD3 was assessed by flow cytometry.
Cells were incubated for 20mins at room temperature with
Mouse BD Fc Block
TM
(BD Biosciences, Oxford, UK) then for
40mins at 41C in the dark, with APC-conjugated rat anti-mouse
antibodies against CD40 or CD86 (eBioscience, San Diego, CA).
Appropriate isotype controls were used. Flow cytometric data
collection was carried out with a BD FACSARIAII SORP (BD
Biosciences, Oxford, UK), using a 640 nm laser (670/14 nm
bandpass filter). Data were analyzed using the FlowJo Version
7.5.5 (Treestar, Olten, Switzerland) and statistical analysis
carried out using one-way ANOVA with Tukey post test.
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